- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Quadrantectomy.
Displaying page 1 of 1.
EudraCT Number: 2005-004263-35 | Sponsor Protocol Number: CFEM345D2411 | Start Date*: 2006-03-24 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer | ||
Medical condition: This study will be a head to head comparison of letrozole versus anastrozole in the adjuvant treatment of high risk patients. Post-menopausal patients who recently have undergone their primary surg... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: IE (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) AT (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-002202-18 | Sponsor Protocol Number: INT 07/07 | Start Date*: 2008-01-11 | ||||||||||||||||||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | ||||||||||||||||||||||||||||
Full Title: CALENDULA POMADE VERSUS PLACEBO CREAM/CORTISONE CREAM (FLUORCORTOLONE) IN THE PREVENTION OF CUTANEOUS ERYTHEMA DUE TO BREAST IRRADIATION. A RANDOMIZED STUDY ON 60 PATIENTS | ||||||||||||||||||||||||||||
Medical condition: Patients treated for the first time with radiotherapy to the residual breast after quadrantectomy for proven non-metastatic breast cancer. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001484-64 | Sponsor Protocol Number: IBCSG 27-02/BIG 1-02/GEICAM 2002/04 | Start Date*: 2006-04-06 | |||||||||||
Sponsor Name:International Breast Cancer Study Group (IBCSG) | |||||||||||||
Full Title: Chemotherapy for Radically Resected Loco-regional Relapse A randomized clinical trial of adjuvant chemotherapy for radically resected loco-regional relapse of breast cancer Chemotherapy vs. Observa... | |||||||||||||
Medical condition: Patients with radically treated isolated local and/or regional recurrence of invasive breast cancer after mastectomy or breast-conserving surgery. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005666-36 | Sponsor Protocol Number: IBCSG 22-00 | Start Date*: 2009-12-07 | |||||||||||
Sponsor Name:International Breast Cancer Study Group | |||||||||||||
Full Title: Low-dose Cytotoxics as “Anti-angiogenesis Treatment” following Adjuvant Induction Chemotherapy for Patients with ER-negative and PgR-negative Breast Cancer Maintenance Chemotherapy in Hormone Non-... | |||||||||||||
Medical condition: Histologically proven ER-negative and PgRnegative breast cancer with either a total mastectomy with axillary clearance or a lesser procedure with axillary lymph node dissection or sentinel node pro... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002626-59 | Sponsor Protocol Number: 26-02/BIG 4-02 | Start Date*: 2005-11-21 | |||||||||||
Sponsor Name:International Breast Cancer Study Group (IBCSG) | |||||||||||||
Full Title: A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy | |||||||||||||
Medical condition: Premenopausal women with histologically proven, resected breast cancer with ER and/or PgR positive tumors for whom there is an uncertain role for adding chemotherapy to the adjuvant treatment program | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000168-28 | Sponsor Protocol Number: IBCSG25-02/BIG3-02 | Start Date*: 2005-11-21 | |||||||||||
Sponsor Name:International Breast Cancer Study Group (IBCSG) | |||||||||||||
Full Title: A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer | |||||||||||||
Medical condition: Premenopausal women with histologically proven, resected breast cancer with ER and/or PgR positive tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000166-13 | Sponsor Protocol Number: 24-02 | Start Date*: 2005-05-12 | |||||||||||
Sponsor Name:International Breast Cancer Study Group (IBCSG) | |||||||||||||
Full Title: A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer. | |||||||||||||
Medical condition: Histologically proven, resected breast cancer with ER and/or PgR positive tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) SE (Completed) DE (Completed) ES (Completed) IE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003509-41 | Sponsor Protocol Number: GBG90 | Start Date*: 2016-08-01 | |||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||
Full Title: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patien... | |||||||||||||
Medical condition: Patients with triple negative or HRpositive, early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001755-72 | Sponsor Protocol Number: GBG88 | Start Date*: 2016-11-22 | |||||||||||
Sponsor Name:German Breast Group | |||||||||||||
Full Title: Investigating Denosumab as an add-on to neoadjuvant chemotherapy in RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules in a 2x2 factorial design (Ge... | |||||||||||||
Medical condition: Patients with early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001155-13 | Sponsor Protocol Number: GBG-99-GeparTREIZE | Start Date*: 2019-04-02 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:GBG Forschungs GmbH | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase III, Randomized, Open-Label Study Investigating the Addition of Durvalumab to an Anthracycline-Taxane based Chemotherapy in Early-Stage Triple-Negative Breast Cancer | ||||||||||||||||||||||||||||||||||||||
Medical condition: Early-staged triple-negative breast cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003330-16 | Sponsor Protocol Number: GBG74 | Start Date*: 2013-02-26 | |||||||||||
Sponsor Name:GBG Forschungs GmbH (German Breast Group) | |||||||||||||
Full Title: Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or lum... | |||||||||||||
Medical condition: Breast Cancer in patients with operable Triple Negative or luminal B/HER2 normal patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002714-72 | Sponsor Protocol Number: GBG89 | Start Date*: 2016-03-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4736 to a taxane-anthracycline containing chemotherapy in triple negative breast cancer. (GeparNuevo) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with triple negative, early breast cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
